NTRK1-rearranged histiocytosis: clinicopathologic and molecular features
Publication date
2025-07-22
Authors
Fragneau, Rivers
Fraitag, Sylvie
Kemps, Paul G.
Hélias-Rodzewicz, Zofia
Roy, Somak
Bonsang, Benjamin
Bartlett, Allison L.
Dhar, Subhra
Jankofsky, Martin
Zlocha, Jozef
Editors
Advisors
Supervisors
Document Type
Article
Metadata
Show full item recordCollections
License
cc_by_nc_nd
Abstract
Non-Langerhans cell histiocytoses are a diverse group of histiocytic diseases. Different entities are defined based on clinical, histopathologic, and/or molecular characteristics. This study aimed to define NTRK-rearranged histiocytosis. Through international collaboration, we investigated 50 cases of histiocytosis with pan-tropomyosin receptor kinase (pan-TRK) expression and/or in-frame NTRK rearrangement. We also analyzed 45 control xanthogranulomas using pan-TRK immunohistochemistry and targeted RNA sequencing. Slides were centrally reviewed; clinical and molecular data were collected. The 50 cases comprised 30 children and 20 adults with a median age of 11.5 years (range, 0-73 years) and a male predominance (64%). Most patients (88%) had disease limited to the skin, including a single skin nodule in 41 patients and multiple skin lesions in 3 others. Four newborns presented with skin lesions, hepatomegaly, and thrombocytopenia that required transfusions. The 2 remaining patients had life-threatening lesions of the brain or bronchus. All cases displayed xanthogranuloma histology, often including foamy histiocytes and Touton giant cells. Histiocytes stained positive for pan-TRK in 50 of 50 cases, whereas all 45 control xanthogranulomas without in-frame NTRK fusions stained negative.
Keywords
• NTRK1-rearranged histiocytosis often presents as 1 or multiple cutaneous xanthogranulomas but may rarely involve extracutaneous tissues, • Targeted therapy with the TRK inhibitor larotrectinib is highly effective in patients with severe extracutaneous disease, Hematology
Citation
Fragneau, R, Fraitag, S, Kemps, P G, Hélias-Rodzewicz, Z, Roy, S, Bonsang, B, Bartlett, A L, Dhar, S, Jankofsky, M, Zlocha, J, Svojgr, K, Krsková, L, de Vries, A C H, Verdijk, R M, van Laar, J A M, Leguit, R J, Drabent, P, Carlsen, E D, Ho, J, Karunamurthy, A D, Santi, M, Jullié, M L, Babor, F, Lorsbach, R, van Halteren, A G S, Héritier, S, Diamond, E L, Durham, B H, Kumar, A R, Bhattacharya, A, Haroche, J, Donadieu, J, Borkhardt, A, Picarsic, J L & Emile, J F 2025, 'NTRK1-rearranged histiocytosis : clinicopathologic and molecular features', Blood Advances, vol. 9, no. 14, pp. 3617-3628. https://doi.org/10.1182/bloodadvances.2025016167